ANGLE PLC (LON:AGL,OTCQX:ANPCY) said a review of its ground-breaking liquid biopsy has identified “advantages” to using the technology when treating head and neck cancer patients.
The Parsortix system detects the tell-tell signs of cancer in the form of circulating tumour cells found in the blood.
In the assessment carried out by the University of Birmingham, the device was shown to help accurately assess and grade risk and was also able to help doctors decide treatment options.
Specifically, physicians were able to predict responses to certain medications and spot the failures early so a shift could be made to a more appropriate drug likely to give a better response.
The researcher said the device may even be able to guide doctors as to which of their cancer patients might be candidates for the new immunotherapies coming through.
Being a liquid biopsy, repeat samples were able to be taken. Traditional biopsies take tissue, which can often be a painful process, so the option to make multiple follow-ups is limited.
Finally, the Birmingham team found Parsortix overcame some of the limitations encountered by rival antibody-based liquid systems.
"This review of current research clearly identifies the potential for using CTC liquid biopsies to improve treatment of head and neck cancer,” said Andrew Newland, ANGLE’s chief executive.
“We are pleased that key advantages of ANGLE's Parsortix system have been recognised and believe that head and neck cancer is another opportunity for ANGLE, once we have our own clinical laboratory established."